Tag Archives: Dr. Ed Wirth

Patients with Complete Paralysis Show Additional Recovery of Arm, Hand and Finger Function at 9-months After Treatment with Asterias’ AST-OPC1

Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on at least one side FREMONT, Calif., June 13, 2017 /PRNewswire/ –Asterias Biotherapeutics, Inc. (NYSE MKT: AST), … Continue reading

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Stem Cell Research | Tagged , , | 2 Comments

Early Phase Clinical Trials of Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells (AST-OPC1) in Patients with Subacute SCI

Extensive preclinical testing of AST-OPC1 (formerly GRNOPC1) in animal models of traumatic SCI demonstrated that these cells survive, migrate throughout the injury site, and improve locomotor function. Therefore, a phase 1 clinical trial was initiated to assess the safety of … Continue reading

Posted in Regenerative Medicine, Spinal Research, Stem Cell Research, Unite 2 Fight Paralysis, Working 2 Walk Science & Advocacy Symposium | Tagged ,

Cell-Based Therapies for SCI: Lessons Learned in Planning and Conducting Two Phase 1 Safety Trials Over the Past 18 Years

Ed Wirth, MD, PhD Spinal Cord Injury Clinical Scientist  

Posted in Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Stem Cell Research | Tagged , , , , , , , , , ,